We are live on
!
Find out more
MIG
McGuire Investment Group Portfolio holdings
AUM
$1.14B
1-Year Est. Return
79.59%
This Fund
S&P 500
This Quarter
Est. Return
+25.91%
1 Year Est. Return
+79.59%
3 Year Est. Return
+184.19%
5 Year Est. Return
+218.18%
10 Year Est. Return
–
AUM
$288M
AUM Growth
+$47.8M
(+20%)
Cap. Flow
-$9.48M
Cap. Flow
% of AUM
-3.29%
Top 10 Holdings %
Top 10 Hldgs %
43.22%
Holding
88
New
6
Increased
31
Reduced
34
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARK Genomic Revolution ETF
ARKG
|
+$310K |
| 2 |
Editas Medicine
EDIT
|
+$279K |
| 3 |
Amazon
AMZN
|
+$242K |
| 4 |
Invesco Semiconductors ETF
PSI
|
+$226K |
| 5 |
Adobe
ADBE
|
+$217K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.22M |
| 2 |
IQVIA
IQV
|
+$1.01M |
| 3 |
Stryker
SYK
|
+$897K |
| 4 |
Cboe Global Markets
CBOE
|
+$880K |
| 5 |
Thermo Fisher Scientific
TMO
|
+$848K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.11% |
| 2 | Healthcare | 25.6% |
| 3 | Financials | 12.05% |
| 4 | Industrials | 5.53% |
| 5 | Consumer Staples | 3.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Bristol-Myers Squibb
BMY
$132B
| $265K | 0.09% |
4,510
+6
| +0.1% | +$359 |
|
77
iShares US Aerospace & Defense ETF
ITA
$14.7B
| $256K | 0.09% |
3,106
| – | – |
|
|
78
Adobe
ADBE
$105B
| $255K | 0.09% |
+586
| New | +$217K |
|
79
PepsiCo
PEP
$190B
| $255K | 0.09% |
1,928
| – | – |
|
|
80
Invesco Semiconductors ETF
PSI
$2.5B
| $251K | 0.09% |
+10,320
| New | +$226K |
|
81
Sanofi
SNY
$104B
| $250K | 0.09% |
4,903
+44
| +0.9% | +$2.14K |
|
82
CRISPR Therapeutics
CRSP
$5.17B
| $239K | 0.08% |
+3,251
| New | +$190K |
|
|
CDMO
83
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $231K | 0.08% |
35,199
+21,899
| +165% | +$122K |
|
|
SGMO
84
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $204K | 0.07% |
22,800
+1,000
| +5% | +$9.28K |
|
|
TBIO
85
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $182K | 0.06% |
10,150
| – | – |
|
|
RGLS
86
DELISTED
Regulus Therapeutics
RGLS
| $14K | ﹤0.01% |
2,000
+100
| +5% | +$655 |
|
87
Boston Scientific
BSX
$71.5B
| – | – |
-6,425
| Closed | -$210K |
|
88
Goldman Sachs
GS
$303B
| – | – |
-4,811
| Closed | -$744K |
|
Similar funds
PFCS
SL
MIC
ACM
HMCP
OHIF
WM
AT
McGuire Investment Group's Q2 2020 Portfolio in Review
As of Q2 2020, McGuire Investment Group held 88 positions worth $288M, up 20% from $240M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
McGuire Investment Group withdrew a net $9.48M in Q2 2020, closing 2 positions and reducing 34 holdings. Its most notable exit was Goldman Sachs, an estimated $744K position sold in full.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 26% a quarter earlier, followed by Healthcare and Financials.
Against the trend, McGuire Investment Group opened a new position in ARK Genomic Revolution ETF worth $377K.
- McGuire Investment Group's largest Q2 2020 buy was ARK Genomic Revolution ETF: 7,233 shares worth $377K.
- McGuire Investment Group added most to Avid Bioservices, Inc. Common Stock in Q2 2020, an estimated $122K increase.
- McGuire Investment Group's biggest Q2 2020 reduction was Apple, cutting an estimated $1.22M.
- McGuire Investment Group fully exited Goldman Sachs in Q2 2020, selling an estimated $744K.
- McGuire Investment Group's ten largest holdings make up 43% of its $288M portfolio in Q2 2020.
- McGuire Investment Group opened 6 new positions and closed 2 in Q2 2020.
- McGuire Investment Group's portfolio value rose 20% quarter-over-quarter to $288M.
Based on McGuire Investment Group's 13F filing for Q2 2020, filed 14 Jul 2020.